Medicare Enrolled
Dr. Seeta Trivedi, M.D.
Medical Oncology · Edison, NJ
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Trivedi from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Trivedi?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Trivedi
Dr. Seeta Trivedi is a medical oncology specialist in Edison, NJ, with 17 years of NPI registration. Based on federal Medicare data, Dr. Trivedi performed 53,521 Medicare services across 1,954 unique beneficiaries.
Between the years covered by Open Payments, Dr. Trivedi received a total of $6,167 from 41 pharmaceutical and/or device companies across 89 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Trivedi is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice
▲ Top 14% volume in NJ
$6,167 industry payments
Medicare Practice Summary
Medicare Utilization ↗53,521
Medicare services
Top 14% in NJ for medical oncology
1,954
Unique beneficiaries
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~3,148 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
20,250 | $1 | $3 |
| Pembrolizumab injection (Keytruda) | 9,000 | $42 | $161 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
7,140 | $2 | $10 |
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
7,000 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 4,500 | $19 | $68 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,046 | $0 | $0 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
874 | $67 | $249 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
556 | $8 | $32 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
451 | $8 | $23 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
439 | $104 | $422 |
| Complete blood count (CBC), automated An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood. |
415 | $6 | $14 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
346 | $12 | $48 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
287 | $71 | $299 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
190 | $26 | $100 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
164 | $117 | $464 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
105 | $58 | $228 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
95 | $66 | $254 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
87 | $29 | $116 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
80 | $103 | $421 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
75 | $143 | $591 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
63 | $14 | $53 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
53 | $1 | $3 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 50 | $333 | $1,478 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
41 | $141 | $573 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
35 | $1 | $6 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
33 | $18 | $70 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
28 | $102 | $375 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
27 | $25 | $97 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
27 | $133 | $547 |
| New patient office visit, complex (60-74 min) | 27 | $179 | $720 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
24 | $59 | $232 |
| Transitional care management services, moderate complexity Services provided to coordinate care during the transition from an inpatient or other facility setting back to the community. This includes follow-up and management of a health problem of at least moderate complexity. |
13 | $174 | $678 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
38.8% high complexity
55.0% medium
6.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$6,167
Total received (2018-2024)
Avg $881/year across 7 years
Top 22% in NJ for medical oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
41
Companies
89
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$3,712 (60.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,960 (31.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$495 (8.0%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$136
2023
$1,375
2022
$3,175
2021
$61
2020
$294
2019
$769
2018
$357
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Mirati Therapeutics, Inc.
$44
Daiichi Sankyo Inc.
$25
Merck Sharp & Dohme LLC
$19
Regeneron Healthcare Solutions, Inc.
$17
PUMA BIOTECHNOLOGY, INC.
$16
Celgene Corporation
$15
Top 3 companies account for 64.9% of 2024 payments
All-time payments by company (2018-2024) ›
Daiichi Sankyo Inc.
$1,542
E.R. Squibb & Sons, L.L.C.
$1,512
Stemline Therapeutics Inc.
$920
Amgen Inc.
$335
Novartis Pharmaceuticals Corporation
$161
Janssen Biotech, Inc.
$130
Exelixis Inc.
$128
Epizyme, Inc.,
$125
Karyopharm Therapeutics Inc.
$125
Alexion Pharmaceuticals, Inc.
$124
Seagen Inc.
$94
Blueprint Medicines Corporation
$93
Celgene Corporation
$92
PFIZER INC.
$75
AstraZeneca Pharmaceuticals LP
$74
Astellas Pharma US Inc
$63
Janssen Scientific Affairs, LLC
$50
Mirati Therapeutics, Inc.
$44
Bayer HealthCare Pharmaceuticals Inc.
$42
Gilead Sciences, Inc.
$37
Genentech USA, Inc.
$36
EISAI INC.
$29
Merck Sharp & Dohme Corporation
$28
Lilly USA, LLC
$27
AbbVie, Inc.
$24
Sirtex Medical Inc
$22
Pharmacosmos Therapeutics Inc.
$21
Merck Sharp & Dohme LLC
$19
Seattle Genetics, Inc.
$18
Eisai Inc.
$17
Regeneron Healthcare Solutions, Inc.
$17
Sumitomo Pharma America, Inc.
$16
PUMA BIOTECHNOLOGY, INC.
$16
Spectrum Pharmaceuticals Inc.
$16
GENZYME CORPORATION
$15
EMD Serono, Inc.
$14
Clovis Oncology, Inc.
$14
Puma Biotechnology, Inc.
$13
Boston Scientific Corporation
$13
Mitsubishi Tanabe Pharma America, Inc.
$11
Incyte Corporation
$11
Top 3 companies account for 64.4% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · Alecensa · Aliqopa · BAVENCIO · Bavencio · CALQUENCE · CYRAMZA · Cabometyx · DARZALEX · ELIQUIS · ENHERTU · ERBITUX · ERLEADA · Enhertu · FASLODEX · GAZYVA · IBRANCE · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · KRAZATI · LIBTAYO · LUMAKRAS · LYNPARZA · Lenvima · MONOFERRIC · Nerlynx · Neulasta · OPDIVO · ORGOVYX · Orserdu · PROMACTA · Pomalyst · REBLOZYL · ROLVEDON · Radicava · Revlimid · Rubraca · SANDOSTATIN · SANDOSTATIN LAR · SCEMBLIX · SIMPONI ARIA · SIR-Spheres Microspheres · Stivarga · TAGRISSO · TAZVERIK · Venclexta · WATCHMAN · XOSPATA · XPOVIO · XTANDI · Xofigo · Xtandi
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (60%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
Medical oncologists within 10 mi
181
Per 100K population
21.0
County median income
$109,028
Nearest hospital
ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL AT RAHWAY
4.9 mi
4.9 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Trivedi is a mixed practice specialist, with above-average Medicare volume (top 14% in NJ), with consulting-driven industry engagement, with 17 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Trivedi experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Trivedi performed 20,250 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Trivedi receive payments from pharmaceutical companies?
Yes. Dr. Trivedi received a total of $6,167 from 41 companies across 89 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Trivedi's costs compare to other medical oncologists in Edison?
Dr. Trivedi's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Trivedi) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologists in Edison
Browse medical oncologists in Edison ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologists in NJ
Medical oncologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologists in NJ
Which NJ medical oncologists receive the most from drug and device companies.
By company
Daiichi Sankyo Inc. Payments to Doctors
See all physicians who received payments from Daiichi Sankyo Inc.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Stemline Therapeutics Inc. Payments to Doctors
See all physicians who received payments from Stemline Therapeutics Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology